NORMAN EBERHARDT

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma
    Bryan McIver
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Curr Drug Targets Immune Endocr Metabol Disord 4:221-34. 2004
  2. pmc The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer
    Norman L Eberhardt
    Department of Medicine, Division of Endocrinology, Mayo Clinic and Foundation, Rochester, MN 55905, United States
    Mol Cell Endocrinol 321:50-6. 2010
  3. pmc A simple method for gene phasing using mate pair sequencing
    Kendall W Cradic
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    BMC Med Genet 15:19. 2014
  4. pmc The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer
    Kimberly A Placzkowski
    Division of Endocrinology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    PPAR Res 2008:672829. 2008
  5. ncbi request reprint PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value
    Mustafa Sahin
    Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 90:463-8. 2005
  6. pmc Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis
    Alicia Algeciras-Schimnich
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Clin Chem 56:391-8. 2010
  7. ncbi request reprint The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition
    J Gregory Powell
    Department of Medicine, Division of Endocrinology, Mayo Clinic, Rochester, MN 55906, USA
    Oncogene 23:3634-41. 2004
  8. ncbi request reprint The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis
    Honey V Reddi
    Department of Medicine Division of Endocrinology, 200 First Street SW, Mayo Clinic, Rochester, MN 55905, USA
    Endocrinology 148:932-5. 2007
  9. pmc hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications
    Yuning Xiong
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Gynecol Oncol 103:321-8. 2006
  10. ncbi request reprint Thyroid gland clonality revisited: the embryonal patch size of the normal human thyroid gland is very large, suggesting X-chromosome inactivation tumor clonality studies of thyroid tumors have to be interpreted with caution
    Lidija Jovanovic
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington 6002, New Zealand
    J Clin Endocrinol Metab 88:3284-91. 2003

Collaborators

  • Bryan McIver
  • I D Hay
  • Mustafa Sahin
  • T J Sebo
  • Sean C Dowdy
  • Stefan K G Grebe
  • Honey V Reddi
  • Kendall W Cradic
  • Alicia Algeciras-Schimnich
  • Kimberly A Placzkowski
  • Yuning Xiong
  • J Gregory Powell
  • Lidija Jovanovic
  • Xiao Li Wang
  • Brett Delahunt
  • Kathryn Farrand
  • Robert A Sikkink
  • George Vasmatzis
  • Stephen J Murphy
  • Travis M Drucker
  • Claudia Neuhauser
  • Dragana Milosevic
  • Heather Flynn
  • Shi Wen Jiang
  • Karl C Podratz
  • Xiying Wang
  • Todd G Kroll
  • Brandon L Allard
  • Seema S Deshpande
  • Henry J Hiddinga
  • John R Goellner

Detail Information

Publications11

  1. ncbi request reprint The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma
    Bryan McIver
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Curr Drug Targets Immune Endocr Metabol Disord 4:221-34. 2004
    ..Alternatively, modulation of several down-stream regulatory pathways may become possible, as the consequences of PPARgamma inhibition become better known. PPFP represents a potential novel target for the management of advanced FTC...
  2. pmc The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer
    Norman L Eberhardt
    Department of Medicine, Division of Endocrinology, Mayo Clinic and Foundation, Rochester, MN 55905, United States
    Mol Cell Endocrinol 321:50-6. 2010
    ..Here we review progress on the studies of PPFP that assess its involvement in FTC tumorigenesis...
  3. pmc A simple method for gene phasing using mate pair sequencing
    Kendall W Cradic
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    BMC Med Genet 15:19. 2014
    ..Several methods are currently used to phase genes, however due to cost, complexity and/or low sensitivity they are not suitable for clinical purposes...
  4. pmc The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer
    Kimberly A Placzkowski
    Division of Endocrinology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    PPAR Res 2008:672829. 2008
    ..PPARgamma agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents...
  5. ncbi request reprint PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value
    Mustafa Sahin
    Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 90:463-8. 2005
    ..g. during intraoperative frozen section). PPARgamma staining also shows an association with favorable prognosis and may have a role in risk stratification...
  6. pmc Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis
    Alicia Algeciras-Schimnich
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Clin Chem 56:391-8. 2010
    ..The molecular changes associated with follicular thyroid carcinoma (FTC) are point mutations in RAS oncogenes or the presence of PAX8/PPARG (paired box 8/peroxisome proliferator-activated receptor gamma) rearrangement...
  7. ncbi request reprint The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition
    J Gregory Powell
    Department of Medicine, Division of Endocrinology, Mayo Clinic, Rochester, MN 55906, USA
    Oncogene 23:3634-41. 2004
    ..Our data suggest that PPFP contributes to malignant transformation during FTC oncogenesis by acting on several cellular pathways, at least some of which are normally regulated by PPARgamma...
  8. ncbi request reprint The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis
    Honey V Reddi
    Department of Medicine Division of Endocrinology, 200 First Street SW, Mayo Clinic, Rochester, MN 55905, USA
    Endocrinology 148:932-5. 2007
    ..PPFP is detected in approximately 30% of FTC. In this report we review data on the role of PPFP in FTC, its mechanism of oncogenesis, and PPFP targeting as a strategy in thyroid cancer treatment...
  9. pmc hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications
    Yuning Xiong
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Gynecol Oncol 103:321-8. 2006
    ..To study how the occupancy of methyl CpG binding domain proteins (MBDs) and histone acetylation/methylation in hMLH1 promoter may participate in hMLH1 silencing...
  10. ncbi request reprint Thyroid gland clonality revisited: the embryonal patch size of the normal human thyroid gland is very large, suggesting X-chromosome inactivation tumor clonality studies of thyroid tumors have to be interpreted with caution
    Lidija Jovanovic
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington 6002, New Zealand
    J Clin Endocrinol Metab 88:3284-91. 2003
    ..Therefore, monoclonality in neoplastic and hyperplastic lesions may just be a reflection of normal thyroid epithelium clonal composition...
  11. ncbi request reprint High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene
    Kathryn Farrand
    Department of Pathology and Molecular Medicine, Wellington School of Medicine, New Zealand
    J Clin Endocrinol Metab 87:4715-21. 2002
    ..These data suggest that a TSG, involved in HCC pathogenesis, is contained within the D17S1308-D17S695 interval. There are several potential candidate TSGs in this region that are worthy of further study...